294 related articles for article (PubMed ID: 10467133)
1. Structural basis for selective inhibition of Src family kinases by PP1.
Liu Y; Bishop A; Witucki L; Kraybill B; Shimizu E; Tsien J; Ubersax J; Blethrow J; Morgan DO; Shokat KM
Chem Biol; 1999 Sep; 6(9):671-8. PubMed ID: 10467133
[TBL] [Abstract][Full Text] [Related]
2. The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases.
Tatton L; Morley GM; Chopra R; Khwaja A
J Biol Chem; 2003 Feb; 278(7):4847-53. PubMed ID: 12475982
[TBL] [Abstract][Full Text] [Related]
3. Src-Abl tyrosine kinase chimeras: replacement of the adenine binding pocket of c-Abl with v-Src to swap nucleotide and inhibitor specificities.
Liu Y; Witucki LA; Shah K; Bishop AC; Shokat KM
Biochemistry; 2000 Nov; 39(47):14400-8. PubMed ID: 11087392
[TBL] [Abstract][Full Text] [Related]
4. Kinase pathways in chemoattractant-induced degranulation of neutrophils: the role of p38 mitogen-activated protein kinase activated by Src family kinases.
Mócsai A; Jakus Z; Vántus T; Berton G; Lowell CA; Ligeti E
J Immunol; 2000 Apr; 164(8):4321-31. PubMed ID: 10754332
[TBL] [Abstract][Full Text] [Related]
5. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
6. Engineering Src family protein kinases with unnatural nucleotide specificity.
Liu Y; Shah K; Yang F; Witucki L; Shokat KM
Chem Biol; 1998 Feb; 5(2):91-101. PubMed ID: 9495830
[TBL] [Abstract][Full Text] [Related]
7. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors.
Zhu X; Kim JL; Newcomb JR; Rose PE; Stover DR; Toledo LM; Zhao H; Morgenstern KA
Structure; 1999 Jun; 7(6):651-61. PubMed ID: 10404594
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis for p38 protein kinase inhibitor specificity.
Lisnock J; Tebben A; Frantz B; O'Neill EA; Croft G; O'Keefe SJ; Li B; Hacker C; de Laszlo S; Smith A; Libby B; Liverton N; Hermes J; LoGrasso P
Biochemistry; 1998 Nov; 37(47):16573-81. PubMed ID: 9843424
[TBL] [Abstract][Full Text] [Related]
9. Inhibitor scaffolds as new allele specific kinase substrates.
Kraybill BC; Elkin LL; Blethrow JD; Morgan DO; Shokat KM
J Am Chem Soc; 2002 Oct; 124(41):12118-28. PubMed ID: 12371851
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors.
Blencke S; Zech B; Engkvist O; Greff Z; Orfi L; Horváth Z; Kéri G; Ullrich A; Daub H
Chem Biol; 2004 May; 11(5):691-701. PubMed ID: 15157880
[TBL] [Abstract][Full Text] [Related]
11. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase.
Wilson KP; McCaffrey PG; Hsiao K; Pazhanisamy S; Galullo V; Bemis GW; Fitzgibbon MJ; Caron PR; Murcko MA; Su MS
Chem Biol; 1997 Jun; 4(6):423-31. PubMed ID: 9224565
[TBL] [Abstract][Full Text] [Related]
12. Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution.
Eyers PA; Craxton M; Morrice N; Cohen P; Goedert M
Chem Biol; 1998 Jun; 5(6):321-8. PubMed ID: 9653550
[TBL] [Abstract][Full Text] [Related]
13. Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket.
Gum RJ; McLaughlin MM; Kumar S; Wang Z; Bower MJ; Lee JC; Adams JL; Livi GP; Goldsmith EJ; Young PR
J Biol Chem; 1998 Jun; 273(25):15605-10. PubMed ID: 9624152
[TBL] [Abstract][Full Text] [Related]
14. The pp60c-Src inhibitor PP1 is non-competitive against ATP.
Karni R; Mizrachi S; Reiss-Sklan E; Gazit A; Livnah O; Levitzki A
FEBS Lett; 2003 Feb; 537(1-3):47-52. PubMed ID: 12606029
[TBL] [Abstract][Full Text] [Related]
15. Effects of protein tyrosine kinase inhibitors on voltage-operated calcium channel currents in vascular smooth muscle cells and pp60(c-src) kinase activity.
Wijetunge S; Lymn JS; Hughes AD
Br J Pharmacol; 2000 Apr; 129(7):1347-54. PubMed ID: 10742290
[TBL] [Abstract][Full Text] [Related]
16. A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase.
Fox T; Coll JT; Xie X; Ford PJ; Germann UA; Porter MD; Pazhanisamy S; Fleming MA; Galullo V; Su MS; Wilson KP
Protein Sci; 1998 Nov; 7(11):2249-55. PubMed ID: 9827991
[TBL] [Abstract][Full Text] [Related]
17. Peroxynitrite modulates the activation of p38 and extracellular regulated kinases in PC12 cells.
Jope RS; Zhang L; Song L
Arch Biochem Biophys; 2000 Apr; 376(2):365-70. PubMed ID: 10775424
[TBL] [Abstract][Full Text] [Related]
18. A dual inhibitor of platelet-derived growth factor beta-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling.
Waltenberger J; Uecker A; Kroll J; Frank H; Mayr U; Bjorge JD; Fujita D; Gazit A; Hombach V; Levitzki A; Böhmer FD
Circ Res; 1999 Jul; 85(1):12-22. PubMed ID: 10400906
[TBL] [Abstract][Full Text] [Related]
19. Ribotoxic stress response to the trichothecene deoxynivalenol in the macrophage involves the SRC family kinase Hck.
Zhou HR; Jia Q; Pestka JJ
Toxicol Sci; 2005 Jun; 85(2):916-26. PubMed ID: 15772366
[TBL] [Abstract][Full Text] [Related]
20. Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1.
Krystal GW; DeBerry CS; Linnekin D; Litz J
Cancer Res; 1998 Oct; 58(20):4660-6. PubMed ID: 9788619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
